BR0012926A - Polipeptìdeos quiméricos, método para a sua produção e seus usos - Google Patents

Polipeptìdeos quiméricos, método para a sua produção e seus usos

Info

Publication number
BR0012926A
BR0012926A BR0012926-7A BR0012926A BR0012926A BR 0012926 A BR0012926 A BR 0012926A BR 0012926 A BR0012926 A BR 0012926A BR 0012926 A BR0012926 A BR 0012926A
Authority
BR
Brazil
Prior art keywords
polypeptide chain
production
polypeptide
cysteines
amino acids
Prior art date
Application number
BR0012926-7A
Other languages
English (en)
Inventor
Hauke Lilie
Susanne Richter
Rainer Rudolf
Kay-Gunnar Stubenrauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0012926A publication Critical patent/BR0012926A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: "POLIPEPTìDEOS QUIMéRICOS, MéTODO PARA A SUA PRODUçãO E SEUS USOS". Um polipeptídeo quimérico consistindo em uma primeira e uma segunda cadeia de polipeptídeo, sendo quimicamente ligado por 1 a 3 pontes dissulfeto à base de cisteína, caracterizado pelo fato de que a dita primeira cadeia de polipeptídeo consiste em 1 a 3 cisteínas e 4 a 12 aminoácidos básicos de preferência selecionados do grupo consistindo em arginina, lisina e ornitinina e a dita segunda cadeia de polipeptídeo consiste em 1 a 3 cisteínas e 4 a 12 aminoácidos ácidos selecionados do grupo consistindo em glutamato e aspartato, e cada uma das ditas cadeias de polipeptídeo é ligada ao seu terminal C ou N a um composto biologicamente ativo, é útil como um agente farmacêutico multimérico.
BR0012926-7A 1999-08-02 2000-07-31 Polipeptìdeos quiméricos, método para a sua produção e seus usos BR0012926A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115022A EP1074563A1 (en) 1999-08-02 1999-08-02 Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
PCT/EP2000/007378 WO2001009193A1 (en) 1999-08-02 2000-07-31 Chimeric polypeptides, method for production and uses thereof

Publications (1)

Publication Number Publication Date
BR0012926A true BR0012926A (pt) 2002-04-30

Family

ID=8238697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012926-7A BR0012926A (pt) 1999-08-02 2000-07-31 Polipeptìdeos quiméricos, método para a sua produção e seus usos

Country Status (17)

Country Link
US (1) US6437095B1 (pt)
EP (2) EP1074563A1 (pt)
JP (1) JP4011914B2 (pt)
KR (1) KR100484084B1 (pt)
CN (1) CN1184235C (pt)
AR (1) AR021448A1 (pt)
AT (1) ATE353921T1 (pt)
AU (1) AU768645B2 (pt)
BR (1) BR0012926A (pt)
CA (1) CA2380569C (pt)
DE (1) DE60033405T2 (pt)
DK (1) DK1206495T3 (pt)
ES (1) ES2280231T3 (pt)
MX (1) MXPA02001139A (pt)
TR (1) TR200200252T2 (pt)
WO (1) WO2001009193A1 (pt)
ZA (1) ZA200109746B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
US7335361B2 (en) * 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
US7550557B2 (en) 2003-08-29 2009-06-23 Louisiana Tech University Foundation, Inc. Multilayer films, coatings, and microcapsules comprising polypeptides
US7544770B2 (en) * 2003-08-29 2009-06-09 Louisiana Tech Foundation, Inc. Multilayer films, coatings, and microcapsules comprising polypeptides
US7348399B2 (en) * 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
MX2007006099A (es) * 2004-11-22 2007-11-07 Univ Louisiana Tech Foundation Metodo para disenar polipeptidos para la nanofabricacion de peliculas delgadas, recubrimientos y microcapsulas mediante el autoensamble de capa por capa electrostatico.
JP2008524203A (ja) * 2004-12-17 2008-07-10 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 分子イメージングのためのターゲティング剤
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2655414B1 (en) 2010-12-23 2018-08-29 Roche Diagniostics GmbH Bispecific binding agent
WO2012085069A2 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a polypeptide dimer by a bivalent binding agent
WO2012085064A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
WO2012107932A1 (en) * 2011-02-11 2012-08-16 Transgene Biotek Ltd. B cell clonal immunotoxin and use thereof
BR112013032235A2 (pt) 2011-06-15 2016-11-22 Hoffmann La Roche anticorpos do receptor de epo anti-humano e métodos de uso
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
JP6445429B2 (ja) 2012-06-27 2018-12-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる標的化実体を含むテーラーメイドで選択的かつ多重特異性治療用分子を選択および作製するための方法およびその使用
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
MX371403B (es) 2014-03-20 2020-01-29 Bristol Myers Squibb Co Moleculas de andamiaje a base de fibronectina estabilizada.
SI3151921T1 (sl) 2014-06-06 2019-12-31 Bristol-Myers Squibb Company Protitelesa proti z glukortikoidom induciranim receptorjem za faktor nekroze tumorja(GITR) in njihova uporaba
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
EP3224277B1 (en) 2014-11-25 2020-08-26 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
JP6738348B2 (ja) 2014-12-19 2020-08-12 リジェネサンス ベスローテン フェンノートシャップ ヒトｃ６に結合する抗体およびその使用
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
HRP20230060T1 (hr) 2015-05-29 2023-03-17 Bristol-Myers Squibb Company Antitijela protiv ox40 i njihova primjena
JP6951340B2 (ja) 2015-09-23 2021-10-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ グリピカン−３結合フィブロネクチンベース足場分子
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
KR102397783B1 (ko) 2016-06-01 2022-05-12 브리스톨-마이어스 스큅 컴퍼니 Pd-l1 결합 폴리펩티드에 의한 pet 영상화
TWI780057B (zh) 2016-07-14 2022-10-11 美商必治妥美雅史谷比公司 針對tim3之抗體及其用途
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
TWI832600B (zh) 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
KR20200108870A (ko) 2018-01-12 2020-09-21 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
MX2020009861A (es) 2018-03-23 2020-10-08 Bristol Myers Squibb Co Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
MA52190A (fr) 2018-04-02 2021-02-17 Bristol Myers Squibb Co Anticorps anti-trem-1 et utilisations associées
EP3841124A4 (en) 2018-06-29 2022-03-23 ApitBio, Inc. ANTI-L1CAM ANTIBODIES AND THEIR USES
PE20212305A1 (es) 2019-01-22 2021-12-10 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用
CN114144435B (zh) 2019-07-15 2024-06-25 百时美施贵宝公司 针对人trem-1的抗体及其用途
CN114174536A (zh) 2019-07-15 2022-03-11 百时美施贵宝公司 抗trem-1抗体及其用途
CN112694527B (zh) * 2020-12-25 2022-09-09 山东睿鹰制药集团有限公司 一种重组人干扰素-κ包涵体的纯化和复性方法
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK132892D0 (da) * 1992-10-30 1992-10-30 Novo Nordisk As Proteiner
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE69830901T2 (de) * 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen

Also Published As

Publication number Publication date
MXPA02001139A (es) 2002-08-20
ATE353921T1 (de) 2007-03-15
CA2380569C (en) 2008-01-22
KR100484084B1 (ko) 2005-04-20
EP1074563A1 (en) 2001-02-07
DK1206495T3 (da) 2007-06-11
ES2280231T3 (es) 2007-09-16
CA2380569A1 (en) 2001-02-08
DE60033405D1 (de) 2007-03-29
AU768645B2 (en) 2003-12-18
KR20020026558A (ko) 2002-04-10
CN1358198A (zh) 2002-07-10
CN1184235C (zh) 2005-01-12
AR021448A1 (es) 2002-07-17
DE60033405T2 (de) 2007-10-31
WO2001009193A1 (en) 2001-02-08
US6437095B1 (en) 2002-08-20
JP2003506028A (ja) 2003-02-18
AU6161000A (en) 2001-02-19
ZA200109746B (en) 2003-03-12
EP1206495A1 (en) 2002-05-22
JP4011914B2 (ja) 2007-11-21
TR200200252T2 (tr) 2002-05-21
EP1206495B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
BR0012926A (pt) Polipeptìdeos quiméricos, método para a sua produção e seus usos
DE602006020123D1 (de) Glucagon-like-peptide-2- (glp-2-) analoga
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
DE60141043D1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
UY23561A1 (es) Procedimiento para la preparacion de tnf-muteinas
SE9100799D0 (sv) Recombinant human factor viii derivatives
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
HUP9901411A2 (hu) Aktív sündisznófehérje konjugátum, eljárás ennek előállítására és felhasználása
IT1187828B (it) Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DE68911461D1 (de) Derivate des basischen Mensch-/Rinder-Fibroblastwachstumsfaktors.
ITRM20020277A1 (it) Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
ATE256189T1 (de) Rekombinante lipase aus hundemagen und pharmazeutische zusammensetzungen
FR2633296B1 (fr) Molecules peptidiques a action sur les germes a gram positif
TH13632EX (th) สารคล้ายโพลิเปปไทด์ที่มีฤทธิ์ในการหลั่งฮอร์โมนเจริญเติบโต
MX9504057A (es) Proteina que tiene actividad tpo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2008 DE 30/06/2009.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.11 PUBLICADO NA RPI 2145 DE 14/02/2012.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2008 DE 30/06/2009. TEXTO CORRETO: REFERENTE A(S) 8A, 9A, 10A E 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO NAO CUMPRIMENTO DO DESPACHO 8.6 NA RPI 2008 DE 20/06/2009 E 8.10 NA RPI 2152 DE 03/04/2012